Compare Piramal Healthcare with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs AJANTA PHARMA - Comparison Results

PIRAMAL ENTERPRISES     Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES AJANTA PHARMA PIRAMAL ENTERPRISES/
AJANTA PHARMA
 
P/E (TTM) x 13.7 21.4 63.9% View Chart
P/BV x 0.9 3.8 23.0% View Chart
Dividend Yield % 2.0 0.9 218.3%  

Financials

 PIRAMAL ENTERPRISES   AJANTA PHARMA
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-19
AJANTA PHARMA
Mar-19
PIRAMAL ENTERPRISES/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs3,3031,422 232.3%   
Low Rs1,797898 200.2%   
Sales per share (Unadj.) Rs716.5233.5 306.8%  
Earnings per share (Unadj.) Rs79.744.0 181.3%  
Cash flow per share (Unadj.) Rs107.952.2 206.9%  
Dividends per share (Unadj.) Rs28.009.00 311.1%  
Dividend yield (eoy) %1.10.8 141.5%  
Book value per share (Unadj.) Rs1,477.5255.1 579.2%  
Shares outstanding (eoy) m184.4588.02 209.6%   
Bonus/Rights/Conversions ISBB-  
Price / Sales ratio x3.65.0 71.7%   
Avg P/E ratio x32.026.4 121.3%  
P/CF ratio (eoy) x23.622.2 106.3%  
Price / Book Value ratio x1.74.5 38.0%  
Dividend payout %35.120.5 171.6%   
Avg Mkt Cap Rs m470,292102,081 460.7%   
No. of employees `0007.86.8 115.0%   
Total wages/salary Rs m22,5044,307 522.5%   
Avg. sales/employee Rs Th16,899.43,022.6 559.1%   
Avg. wages/employee Rs Th2,877.7633.4 454.3%   
Avg. net profit/employee Rs Th1,879.9569.1 330.4%   
INCOME DATA
Net Sales Rs m132,15320,554 643.0%  
Other income Rs m3,128211 1,483.9%   
Total revenues Rs m135,28120,765 651.5%   
Gross profit Rs m66,2905,664 1,170.3%  
Depreciation Rs m5,202721 721.6%   
Interest Rs m44,09712 380,150.0%   
Profit before tax Rs m20,1195,143 391.2%   
Minority Interest Rs m3,1940-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,6111,273 676.5%   
Profit after tax Rs m14,7013,870 379.9%  
Gross profit margin %50.227.6 182.0%  
Effective tax rate %42.824.8 172.9%   
Net profit margin %11.118.8 59.1%  
BALANCE SHEET DATA
Current assets Rs m122,74211,812 1,039.1%   
Current liabilities Rs m310,8103,776 8,230.3%   
Net working cap to sales %-142.339.1 -364.0%  
Current ratio x0.43.1 12.6%  
Inventory Days Days2377 29.8%  
Debtors Days Days3982 47.6%  
Net fixed assets Rs m116,90414,398 811.9%   
Share capital Rs m369175 210.3%   
"Free" reserves Rs m272,16122,277 1,221.7%   
Net worth Rs m272,53022,452 1,213.8%   
Long term debt Rs m270,1967 4,093,881.8%   
Total assets Rs m856,26126,962 3,175.8%  
Interest coverage x1.5444.3 0.3%   
Debt to equity ratio x1.00 337,269.8%  
Sales to assets ratio x0.20.8 20.2%   
Return on assets %6.914.4 47.7%  
Return on equity %5.417.2 31.3%  
Return on capital %12.423.0 54.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,20010,682 142.3%   
Fx outflow Rs m4,8892,102 232.6%   
Net fx Rs m10,3128,580 120.2%   
CASH FLOW
From Operations Rs m-115,9753,748 -3,094.5%  
From Investments Rs m-8,265-2,228 371.0%  
From Financial Activity Rs m107,525-1,475 -7,291.8%  
Net Cashflow Rs m-16,65045 -36,836.7%  

Share Holding

Indian Promoters % 52.9 73.8 71.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.0 1.6 258.1%  
FIIs % 26.6 7.6 350.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 16.5 17.0 97.1%  
Shareholders   93,274 20,968 444.8%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   WYETH LTD  PFIZER  ALKEM LABORATORIES  SHASUN PHARMA  SANOFI INDIA  

Compare PIRAMAL ENTERPRISES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Momentum, Key Q2FY20 Results, and Top Cues in Focus Today(Pre-Open)

On Wednesday, Indian share markets traded on a volatile note throughout the day and ended marginally higher.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 8.4% (Quarterly Result Update)

Aug 2, 2019 | Updated on Aug 2, 2019

For the quarter ended June 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 8.4% YoY). Sales on the other hand came in at Rs 6 bn (up 19.8% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY20); Net Profit Up 390.0% (Quarterly Result Update)

Aug 1, 2019 | Updated on Aug 1, 2019

For the quarter ended June 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 4 bn (up 390.0% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 9, 2019 | Updated on Jul 9, 2019

Here's an analysis of the annual report of PIRAMAL ENTERPRISES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of PIRAMAL ENTERPRISES. Also includes updates on the valuation of PIRAMAL ENTERPRISES.

AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.

AJANTA PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 5.9% (Quarterly Result Update)

May 3, 2019 | Updated on May 3, 2019

For the quarter ended March 2019, AJANTA PHARMA has posted a net profit of Rs 889 m (down 5.9% YoY). Sales on the other hand came in at Rs 5 bn (down 2.9% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Oct 16, 2019 (Close)

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES 5-YR ANALYSIS

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS